Profile data is unavailable for this security.
About the company
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.
- Revenue in USD (TTM)59.65m
- Net income in USD6.85m
- Incorporated2016
- Employees208.00
- LocationProtalix Biotherapeutics Inc2 University Plaza, Suite 100HACKENSACK 07601United StatesUSA
- Phone+1 (201) 696-9345
- Fax+1 (845) 818-3588
- Websitehttps://protalix.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elutia Inc | 25.05m | -49.46m | 79.14m | 54.00 | -- | -- | -- | 3.16 | -2.35 | -2.34 | 1.24 | -2.07 | 0.5219 | 2.06 | 4.27 | 463,833.30 | -103.05 | -42.93 | -599.50 | -79.34 | 42.01 | 43.32 | -197.48 | -64.16 | 0.5499 | -1.36 | -- | -- | -49.69 | -8.71 | -25.39 | -- | 12.74 | -- |
| Serina Therapeutics Inc | 137.00k | -20.96m | 79.17m | 4.00 | -- | -- | -- | 577.92 | -14.07 | -14.07 | 0.0909 | -0.5121 | 0.0117 | -- | 3.86 | 34,250.00 | -179.27 | -194.46 | -- | -- | 67.88 | 85.80 | -15,301.46 | -2,347.36 | -- | -0.9274 | 1.70 | -- | 317.65 | -36.69 | -41.49 | -- | -- | -- |
| Cue Biopharma Inc | 7.02m | -49.97m | 79.29m | 53.00 | -- | 2.64 | -- | 11.29 | -1.07 | -1.07 | 0.1495 | 0.6175 | 0.1035 | -- | 8.80 | 132,452.80 | -73.69 | -57.45 | -96.35 | -68.41 | -- | -- | -711.84 | -810.87 | -- | -- | 0.1935 | -- | 340.88 | 36.88 | 4.30 | -- | -- | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -55.09m | 79.89m | 47.00 | -- | 2.00 | -- | -- | -1.25 | -1.25 | 0.00 | 0.7498 | 0.00 | -- | -- | 0.00 | -53.21 | -48.44 | -56.51 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.5592 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Angion Biomedica Corp | 0.00 | -38.99m | 81.14m | 32.00 | -- | 16.58 | -- | -- | -6.63 | -6.63 | 0.00 | 0.4765 | 0.00 | -- | -- | 0.00 | -117.72 | -105.91 | -133.85 | -331.69 | -- | -- | -- | -712.81 | -- | -- | 0.00 | -- | -100.00 | -- | 9.31 | -- | -- | -- |
| Sellas Life Sciences Group Inc | 0.00 | -35.81m | 81.43m | 16.00 | -- | 8.19 | -- | -- | -1.12 | -1.12 | 0.00 | 0.1721 | 0.00 | -- | -- | 0.00 | -133.77 | -111.48 | -303.59 | -184.29 | -- | -- | -- | -1,289.42 | -- | -- | 0.00 | -- | -100.00 | -- | 9.59 | -- | -- | -- |
| Protalix Biotherapeutics Inc | 59.65m | 6.85m | 82.85m | 208.00 | 18.62 | 2.77 | 10.25 | 1.39 | 0.0607 | 0.0607 | 0.7924 | 0.4077 | 0.7629 | 1.06 | 23.56 | 286,798.10 | 8.76 | -18.70 | 19.55 | -67.14 | 62.28 | 70.01 | 11.48 | -21.93 | 0.9677 | 6.23 | 0.4067 | -- | 37.48 | 13.85 | 155.68 | -- | 10.87 | -- |
| Assembly Biosciences Inc | 12.95m | -51.36m | 83.53m | 65.00 | -- | 2.55 | -- | 6.45 | -11.22 | -11.22 | 2.76 | 5.95 | 0.1276 | -- | 34.07 | 199,200.00 | -50.60 | -39.69 | -66.58 | -44.03 | -- | -- | -396.63 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
| Gritstone bio Inc | 15.65m | -144.89m | 84.00m | 231.00 | -- | 5.44 | -- | 5.37 | -1.57 | -1.57 | 0.17 | 0.1423 | 0.0901 | -- | 40.53 | 67,727.27 | -83.47 | -48.08 | -97.70 | -55.18 | -- | -- | -926.13 | -573.71 | -- | -554.88 | 0.7428 | -- | -18.05 | 68.96 | -15.71 | -- | -4.19 | -- |
| Ikena Oncology Inc | 3.85m | -70.09m | 85.42m | 34.00 | -- | 0.5499 | -- | 22.20 | -1.58 | -1.58 | 0.0861 | 3.22 | 0.0237 | -- | -- | 89,488.38 | -43.11 | -29.72 | -46.56 | -34.62 | -- | -- | -1,821.54 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
| Chimerix Inc | 41.00k | -82.59m | 86.65m | 72.00 | -- | 0.4977 | -- | 2,113.52 | -0.9296 | -0.9296 | 0.0005 | 1.94 | 0.0002 | -- | 0.1226 | 569.44 | -36.50 | -30.45 | -39.59 | -34.09 | 100.00 | -- | -201,443.90 | -442.93 | -- | -- | 0.00 | -- | -99.04 | -46.24 | -147.68 | -- | -13.24 | -- |
| Allovir Inc | 0.00 | -179.53m | 86.82m | 112.00 | -- | 0.7201 | -- | -- | -1.65 | -1.65 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -92.50 | -52.85 | -100.98 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to Protalix Biotherapeutics Inc's reporting currency: US Dollar USD
9.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.99m | 4.09% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 826.58k | 1.13% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 824.70k | 1.13% |
| Geode Capital Management LLCas of 31 Mar 2024 | 754.11k | 1.03% |
| GSA Capital Partners LLPas of 31 Mar 2024 | 493.57k | 0.68% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 430.67k | 0.59% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 299.53k | 0.41% |
| Teachers Advisors LLCas of 31 Mar 2024 | 262.08k | 0.36% |
| Bridgeway Capital Management LLCas of 31 Mar 2024 | 183.79k | 0.25% |
| BlackRock Investment Management LLCas of 31 Mar 2024 | 173.40k | 0.24% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
